Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Randomized, Double-Blind, and Placebo-Controlled Phase 3b Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) on Clinical Response and Inhibition of Radiographic Progression in Participants With Active Psoriatic Arthritis

NCT07871721 is registered in ClinicalTrials.gov with Takeda as lead sponsor.

NCT NCT07871721
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07871721 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Randomized, Double-Blind, and Placebo-Controlled Phase 3b Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) on Clinical Response and Inhibition of Radiographic Progression in Participants With Active Psoriatic Arthritis
Lead sponsor
Takeda
Phase
Phase 3
Overall status
Not yet recruiting
Start date
January 11, 2027
Completion date
December 30, 2030
Enrollment
644 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

psoriatic arthritis